Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Basilea Pharmaceutica AG, Allschwil

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea on track with strong 2025 half-year results
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea provides portfolio update and outlook
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
From Basilea Pharmaceutica AG, Allschwil
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.